Effectiveness and Tolerability of Perampanel in Children and Adolescents with Refractory Epilepsies: First Experiences

Abstract

Objective This article aims to report the first clinical experiences concerning effectiveness and tolerability of perampanel (PER) in a pediatric population with refractory epilepsies.

Patients and Methods This nonsponsored, observational, retrospective survey was conducted through collaboration with multiple centers in Europe. The clinical course of the first pediatric patients treated in these centers with PER was documented with the help of a questionnaire completed by the treating physicians. Effectiveness and adverse effects were evaluated. The study population consisted of 58 patients (mean age, 10.5 years; range, 2–17 years), suffering from various refractory epilepsies, classified as focal epilepsy (n = 36), unclassified generalized epilepsy (n = 12), Lennox–Gastaut syndrome (n = 5), West syndrome (n = 3), and Dravet syndrome (n = 2).

Results The response rate (≥ 50% seizure reduction) after the first 3 months of therapy was 31% (18/58 patients) in total. Complete seizure control was achieved in five patients (9% overall). Aggravation of seizures occurred in five cases (9%). The most frequently occurring adverse effects were reduced vigilance or fatigue (n = 16) and behavioral changes (n = 14).

Discussion PER seems to be effective also in children and adolescents with pharmaco-refractory epilepsies. Tolerability was acceptable.

Keywords

perampanel - pediatric - refractory epilepsies - treatment outcome - adverse effects

• References

• 1 Hanada T, Hashizume Y, Tokuhara N , et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011; 52 (7) 1331-1340
• 2 Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 2012; 61 (4) 517-522
• 3 French JA, Krauss GL, Biton V , et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79 (6) 589-596
• 4 French JA, Krauss GL, Steinhoff BJ , et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54 (1) 117-125
• 5 Krauss GL, Serratosa JM, Villanueva V , et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78 (18) 1408-1415
• 6 European Medicines Agency. Fycompa: EPAR - Product Information. 2012. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf . Accessed August 31, 2014
• 7 Food and Drug Administration. Fycompa – NDA 202834, FDA Approved Labeling Text. 2012 Okt. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf . Accessed August 31, 2014
• 8 Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 2013; 54 (8) 1490-1497
• 9 Steinhoff BJ, Bacher M, Bast T , et al. First clinical experiences with perampanel—the Kork experience in 74 patients. Epilepsia 2014; 55 (Suppl. 01) 16-18
• 10 European Medicines Agency decision P/0160/2014 of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467–PIP01–08–M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. 2014 Jun. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500169857.pdf . Accessed August 31, 2014
• 11 Amann JP, Glauser T, Chiron C. Developing antiepileptic drugs in children: balancing protection and access. Handb Clin Neurol 2013; 111: 741-746
• 12 Berg AT, Berkovic SF, Brodie MJ , et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51 (4) 676-685
• 13 Food and Drug Administration CFR - Code of Federal Regulations Title 21, Volume 5; 21CFR312.32, 2014